Why the study?
Information on the mid-term outcome of cryoballoon ablation for drug-resistant AF in patients with reduced left ventricular systolic function was limited.
Does second-generation cryoballoon ablation prevent atrial fibrillation recurrence in patients with heart failure and reduced ejection fraction?
Does second-generation cryoballoon ablation prevent atrial fibrillation recurrence in patients with heart failure and reduced ejection fraction?
Second-generation cryoballoon ablation is feasible and safe in patients with heart failure and reduced ejection fraction, though mid-term freedom from AF after a single procedure was modest at 42.9%.
Answers are grounded in this paper and cite their sources.
Supports CB-A feasibility in reduced-EF AF; leaves open randomized efficacy and safety trials.
PURPOSE: Currently, information on the mid-term outcome of cryoballoon ablation (CB-A) for drug-resistant atrial fibrillation in patients with reduced left ventricular systolic function is limited. METHODS: Thirty-eight consecutive patients with paroxysmal or persistent atrial fibrillation (84.2% male), with median left ventricular ejection fraction of 37.3% were included in our study. All patients underwent the procedure with the 28-mm cryoballoon advance. RESULTS: There were no mayor complications related to the CB-A procedure. Median follow-up was 26.5 ± 13.7 months. The freedom from atrial fibrillation after a blanking period of 3 months was 42.9% in our cohort of patients. During the follow-up period, 13 patients underwent at least a new electrophysiological procedure. After a single procedure, the univariate predictors of clinical recurrence after the blanking period were age and persistent atrial fibrillation. CONCLUSION: Second-generation CB-A of atrial fibrillation seems feasible and safe in patients with heart failure with reduced ejection fraction and heart failure with mid-range ejection fraction, in terms of complications rate and number of applications per vein. All pulmonary veins could be isolated with the 28-mm cryoballoon advance only.
No takes yet. Share an insight, caveat, or question.
Maj et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: